Insys Therapeutics Inc. (NASDAQ:INSY)’s share price was down 1.1% during mid-day trading on Monday . The company traded as low as $14.70 and last traded at $14.82, with a volume of 228,247 shares traded. The stock had previously closed at $14.98.

A number of equities analysts recently issued reports on INSY shares. Janney Montgomery Scott started coverage on Insys Therapeutics in a research note on Thursday, April 14th. They issued a “buy” rating and a $22.00 target price for the company. Zacks Investment Research upgraded Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, June 29th. Jefferies Group restated a “buy” rating and issued a $23.00 target price on shares of Insys Therapeutics in a research note on Wednesday, March 23rd. Piper Jaffray Cos. reduced their target price on Insys Therapeutics from $46.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, April 11th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $32.00 target price (down previously from $44.00) on shares of Insys Therapeutics in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.83.

The firm’s 50-day moving average price is $14.39 and its 200-day moving average price is $16.56. The company has a market capitalization of $1.07 billion and a price-to-earnings ratio of 21.60.

Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Thursday, April 28th. The specialty pharmaceutical company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.04. The firm had revenue of $62 million for the quarter, compared to analyst estimates of $61.31 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The business’s revenue for the quarter was down 12.4% on a year-over-year basis. Equities research analysts expect that Insys Therapeutics Inc. will post $0.36 earnings per share for the current fiscal year.

In related news, Director Theodore H. Stanley sold 16,000 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $16.27, for a total transaction of $260,320.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at $292,860. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept bought 50,000 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average price of $12.84 per share, with a total value of $642,000.00. Following the purchase, the insider now owns 31,982 shares of the company’s stock, valued at approximately $410,648.88. The disclosure for this purchase can be found here.

A number of institutional investors recently added to or reduced their stakes in INSY. Globeflex Capital L P increased its position in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock valued at $1,135,000 after buying an additional 39,600 shares in the last quarter. California State Teachers Retirement System increased its position in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 754 shares in the last quarter. ProShare Advisors LLC increased its position in Insys Therapeutics by 7.5% in the fourth quarter. ProShare Advisors LLC now owns 61,353 shares of the specialty pharmaceutical company’s stock valued at $1,757,000 after buying an additional 4,305 shares in the last quarter. Bank of Montreal Can increased its position in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 5,733 shares in the last quarter. Finally, Sei Investments Co. increased its position in Insys Therapeutics by 6.6% in the fourth quarter. Sei Investments Co. now owns 78,945 shares of the specialty pharmaceutical company’s stock valued at $2,260,000 after buying an additional 4,854 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.